The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies

Simple item page
dc.contributor.authorSánchez-Martín, David
dc.contributor.authorFogal, Valentina
dc.contributor.authorRuoslahti, Erkki
dc.contributor.authorÁlvarez-Vallina, Luis
dc.contributor.authorCuesta Martínez, Ángel
dc.date.accessioned2024-01-18T10:24:04Z
dc.date.available2024-01-18T10:24:04Z
dc.date.issued2011-02-01
dc.description.abstractTumor-associated cell surface antigens and tumor-associated vascular markers have been used as a target for cancer intervention strategies. However, both types of targets have limitations due to accessibility, low and/or heterogeneous expression, and presence of tumor-associated serum antigen. It has been previously reported that a mitochondrial/cell surface protein, p32/gC1qR, is the receptor for a tumor-homing peptide, LyP-1, which specifically recognizes an epitope in tumor cells, tumor lymphatics, and tumor-associated macrophages/myeloid cells. Using antibody phage technology, we have generated an anti-p32 human monoclonal antibody (2.15). The 2.15 antibody, expressed in single-chain fragment variable and in trimerbody format, was then characterized in vivo using mice grafted subcutaneously with MDA-MB-231 human breast cancers cells, revealing a highly selective tumor uptake. The intratumoral distribution of the antibody was consistent with the expression pattern of p32 in the surface of some clusters of cells. These results demonstrate the potential of p32 for antibody-based tumor targeting strategies and the utility of the 2.15 antibody as targeting moiety for the selective delivery of imaging and therapeutic agents to tumors.
dc.description.departmentDepto. de Bioquímica y Biología Molecular
dc.description.facultyFac. de Farmacia
dc.description.refereedTRUE
dc.description.sponsorshipMinisterio de Ciencia e Innovación
dc.description.sponsorshipComunidad Autónoma de Madrid
dc.description.sponsorshipEuropean Union
dc.description.sponsorshipU. S. Department of Defense Breast Cancer Program
dc.description.sponsorshipSusan Komen Foundation
dc.description.statuspub
dc.identifier.citationSánchez-Martín D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L. The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies. J Biol Chem. 2011;286(7):5197-5203. doi:10.1074/jbc.M110.161927
dc.identifier.doi10.1074/jbc.m110.161927
dc.identifier.issn0021-9258
dc.identifier.officialurlhttps://doi.org/10.1074/jbc.m110.161927
dc.identifier.urihttps://hdl.handle.net/20.500.14352/93792
dc.issue.number7
dc.journal.titleJournal of Biological Chemistry
dc.language.isoeng
dc.page.final5203
dc.page.initial5197
dc.relation.projectIDinfo:eu-repo/grantAgreement/FPI-000531
dc.relation.projectIDinfo:eu-repo/grantAgreement/(BIO2008-03233
dc.relation.projectIDinfo:eu-repo/grantAgreement/S-BIO0236-2006
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.cdu577.1
dc.subject.cdu577.2
dc.subject.ucmBioquímica (Farmacia)
dc.subject.ucmBiología molecular (Farmacia)
dc.subject.unesco24 Ciencias de la Vida
dc.titleThe Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number286
dspace.entity.typePublication
relation.isAuthorOfPublication963e050e-5a67-40d7-8e25-3dc7ff5a8619
relation.isAuthorOfPublication.latestForDiscovery963e050e-5a67-40d7-8e25-3dc7ff5a8619
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2011 - The multicompartmental p32-gClqR as a new target for antibody-based tumor targeting strategies.pdf
Size:
2.19 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos